Lehembre F - Search Results

1

Antitumor compound testing in glioblastoma organotypic brain cultures.

Biggs T, Foreman J, Sundstrom L, Regenass U, Lehembre F. Biggs T, et al. Among authors: lehembre f. J Biomol Screen. 2011 Sep;16(8):805-17. doi: 10.1177/1087057111414895. Epub 2011 Aug 1. J Biomol Screen. 2011. PMID: 21807962

2

Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

Lee HJ, Hanibuchi M, Kim SJ, Yu H, Kim MS, He J, Langley RR, Lehembre F, Regenass U, Fidler IJ. Lee HJ, et al. Among authors: lehembre f. Neuro Oncol. 2016 Apr;18(4):486-96. doi: 10.1093/neuonc/now037. Neuro Oncol. 2016. PMID: 26995790 Free PMC article.

3

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.

Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ. Kim SJ, et al. Among authors: lehembre f. Clin Cancer Res. 2015 Oct 15;21(20):4630-41. doi: 10.1158/1078-0432.CCR-14-3195. Epub 2015 Jun 23. Clin Cancer Res. 2015. PMID: 26106074 Free PMC article.

4

A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor.

Lotz-Jenne C, Lüthi U, Ackerknecht S, Lehembre F, Fink T, Stritt M, Wirth M, Pavan S, Bill R, Regenass U, Christofori G, Meyer-Schaller N. Lotz-Jenne C, et al. Among authors: lehembre f. Oncotarget. 2016 May 3;7(18):25983-6002. doi: 10.18632/oncotarget.8418. Oncotarget. 2016. PMID: 27036020 Free PMC article.

5

Metastatic disease: a drug discovery perspective.

Lehembre F, Regenass U. Lehembre F, et al. Semin Cancer Biol. 2012 Jun;22(3):261-71. doi: 10.1016/j.semcancer.2012.03.005. Epub 2012 Mar 30. Semin Cancer Biol. 2012. PMID: 22484560 Review.

6

Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, Maya M, Zhang F, Wu Q, Lehembre F, Regenass U, Fidler IJ. Kim SJ, et al. Among authors: lehembre f. Neoplasia. 2011 Feb;13(2):167-79. doi: 10.1593/neo.10806. Neoplasia. 2011. PMID: 21403842 Free PMC article.

7

Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.

Kim SJ, Kim JS, Kim SW, Yun SJ, He J, Brantley E, Fan D, Strickner P, Lehembre F, Regenass U, Fidler IJ. Kim SJ, et al. Among authors: lehembre f. Transl Oncol. 2012 Feb;5(1):39-47. doi: 10.1593/tlo.11286. Epub 2012 Feb 1. Transl Oncol. 2012. PMID: 22348175 Free PMC article.

8

Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis.

Yilmaz M, Maass D, Tiwari N, Waldmeier L, Schmidt P, Lehembre F, Christofori G. Yilmaz M, et al. Among authors: lehembre f. EMBO J. 2011 Sep 6;30(21):4489-99. doi: 10.1038/emboj.2011.319. EMBO J. 2011. PMID: 21897365 Free PMC article.

9

NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.

Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, Kren A, Went P, Derksen PW, Berns A, Jonkers J, Christofori G. Lehembre F, et al. EMBO J. 2008 Oct 8;27(19):2603-15. doi: 10.1038/emboj.2008.178. Epub 2008 Sep 4. EMBO J. 2008. PMID: 18772882 Free PMC article.

10

Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton.

Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Wicki A, et al. Among authors: lehembre f. Cancer Cell. 2006 Apr;9(4):261-72. doi: 10.1016/j.ccr.2006.03.010. Cancer Cell. 2006. PMID: 16616332 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results